Indivior Pharmaceuticals, Inc. Common Stock
INDVIndivior PLC is a British pharmaceutical company specializing in the development and marketing of treatments for substance use disorders, including addiction to opioids and alcohol. Founded in 2014 as a spin-off from Reckitt Benckiser, Indivior focuses on innovative medications such as Suboxone for opioid dependence. The company operates globally, providing therapies aimed at improving patient outcomes and addressing the challenges of addiction.
Company News
Herantis Pharma announced positive FDA feedback on its Phase 2a study design for HER-096, a lead candidate for Parkinson's disease treatment. The company has finalized the study design to enroll approximately 100 patients and secured over 50% of Phase 2 funding. The FDA raised no concerns regarding chemistry, manufacturing, controls, or preclinic...
Divisadero Street Capital Management sold 2.26 million shares of Indivior (INDV) for approximately $74.76 million in Q1 2026, reducing its stake to 521,083 shares. The sale appears to be profit-taking after the stock surged nearly 200% over the past year. Despite the fund's exit, Indivior's fundamentals remain strong with Q1 revenue up 19% year-o...
Indivior presented new real-world data at the ASAM 2026 Annual Conference demonstrating that SUBLOCADE (monthly injectable buprenorphine) accounts for the smallest proportion of non-fatal and fatal overdose events compared to other medications for opioid use disorder. The company also presented findings from the ROUTE Study showing that remission...
Indivior Pharmaceuticals (INDV) announced it will report first quarter 2026 financial results on April 30, 2026, followed by a live webcast presentation at 8:00 a.m. EDT with CEO Joe Ciaffoni and leadership team. The company highlighted a cost impact model showing its monthly injectable buprenorphine treatment (SUBLOCADE) may reduce staffing burd...
Indivior Pharmaceuticals priced a $450 million offering of 0.625% convertible senior notes due 2031, upsized from the initially announced $400 million. The notes have a conversion price of approximately $41.66 per share (35% premium to market price) and will mature on March 15, 2031. Net proceeds of approximately $437.7 million will be used to re...
